07/11/19 -"We have made some adjustments to take into account the huge impairment and added some first costs (€120m for 2019-21) in the implementation of the €300-350m cost reduction plan to our P&L. "
Pages
59
Language
English
Published on
07/11/19
You may also be interested by these reports :
27/02/26
BASF’s Q4 2025 sales declined due to pricing pressure despite positive volumes, with Chemicals being most affected by oversupply. Materials saw ...
27/02/26
Arkema’s Q4 2025 earnings lagged behind market estimates amid continued de-stocking and weakness in the U.S. and Europe, with Asia being the only ...
26/02/26
Clariant’s Q4 2025 sales growth was volume-led, with pricing broadly flat. Higher volumes and performance improvement initiatives drove a meaningful ...
26/02/26
Arkema’s Q4 2025 results were broadly weak despite a modest sales beat. Sales declined across segments but exceeded expectations across divisions ...